This analysis examines the current position and future outlook for Novartis in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Benchmark Novartis’ performance against key rivals in the ethical pharmaceutical sector
Evaluate the strength of Novartis’ research pipeline
Understand the drivers of Novartis’ forecast 5.5% year-on-year growth to 2010
